thalidomide has been researched along with Fibrosis, Radiation in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was begun at 50 mg, p." | 1.33 | Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. ( Anscher, MS; Clough, R; Crawford, J; Dewhirst, MW; Dunphy, F; Garst, J; Herndon, JE; Larrier, N; Marino, C; Marks, LB; Shafman, TD; Vujaskovic, Z; Zhou, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anscher, MS | 1 |
| Garst, J | 1 |
| Marks, LB | 1 |
| Larrier, N | 1 |
| Dunphy, F | 1 |
| Herndon, JE | 1 |
| Clough, R | 1 |
| Marino, C | 1 |
| Vujaskovic, Z | 1 |
| Zhou, S | 1 |
| Dewhirst, MW | 1 |
| Shafman, TD | 1 |
| Crawford, J | 1 |
1 other study available for thalidomide and Fibrosis, Radiation
| Article | Year |
|---|---|
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast | 2006 |